Search

Your search keyword '"Barbaud A"' showing total 2 results
2 results on '"Barbaud A"'

1. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis).

Author

Ingen-Housz-Oro S, Matei I, Gaillet A, Gueudry J, Zaghbib K, Assier H, Hua C, Bensaid B, Colin A, Ouedraogo R, Redlich J, Courtois E, Chazelas K, Sbidian E, Nakad L, Bequignon E, Terkmane N, Gaultier F, Schlemmer F, Do-Pham G, Barbaud A, Lebrun-Vignes B, Hoffmann C, Mahé PJ, Le Floch R, Bernier C, Vabres B, Milpied B, Delcampe A, Tétart F, Tauber M, Staumont-Sallé D, Dezoteux F, Descamps V, Misery L, Bursztejn AC, Dereure O, Amazan E, Le Bidre E, Le Pallec S, Lagier C, Laroche A, Ferrat E, Wolkenstein P, and de Prost N

Subjects
Humans, France, Adult, Clinical Protocols, Stevens-Johnson Syndrome diagnosis, Stevens-Johnson Syndrome therapy, Stevens-Johnson Syndrome etiology
Published
2024
Full Text
View/download PDF

2. Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024.

Author

Paireau, Juliette, Durand, Cécile, Raimbault, Sylvain, Cazaubon, Joséphine, Mortamet, Guillaume, Viriot, Delphine, Milesi, Christophe, Daudens‐Vaysse, Elise, Ploin, Dominique, Tessier, Sabrina, Vanel, Noémie, Chappert, Jean‐Loup, Levieux, Karine, Ollivier, Ronan, Daoudi, Jamel, Coignard, Bruno, Leteurtre, Stéphane, Parent‐du‐Châtelet, Isabelle, and Vaux, Sophie

Subjects
PEDIATRIC intensive care, INTENSIVE care units, RESPIRATORY syncytial virus, BRONCHIOLITIS, RESPIRATORY syncytial virus infections
Abstract

In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case–control study based on the test‐negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5–88.7) in the main analysis and 80.6% (61.6–90.3) and 80.4% (61.7–89.9) in two sensitivity analyses. These real‐world estimates confirmed the efficacy observed in clinical studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results